Fabrizio de Ponti (F De Ponti, Fabrizio De Ponti)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 26

Top Venues

Internal and emergency medicine

British journal of clinical pharmacology

Clinical pharmacology and therapeutics

Pharmaceuticals (Basel, Switzerland)

Università degli Studi di Bologna

Università degli Studi di Torino (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Università degli Studi di Bologna Oct 16 2012

Italy

Professor of Pharmacology :: Department of Medical and Surgical Sciences

Università degli Studi di Bologna Nov 01 1998 - Oct 15 2012

Italy

Professor of Pharmacology :: Department of Pharmacology

Università degli Studi di Pavia - Oct 31 1998

Italy

Assistant Professor :: Department of Internal Medicine and Therapeutics

Education History

Università degli Studi di Torino - Oct 31 1989

Italy

PHD

Publications

Carlotta Lunghi, Marco Domenicali, Stefano Vertullo, Emanuel Raschi, Fabrizio de Ponti, Graziano Onder, Elisabetta Poluzzi
Adopting STOPP/START Criteria Version 3 in Clinical Practice: A Q&A Guide for Healthcare Professionals. Drug safety (2024)
Elisabetta Poluzzi, Emanuel Raschi, Carlotta Lunghi, Alice Bertuccio, Andreas Eleftheriou, Fabrizio de Ponti
Learning of clinical pharmacology by future prescribers in Bologna: Teachers' and students' reflections on the way forward. British journal of clinical pharmacology (2024)
Erik M Donker, Pietro Spitaleri Timpone, David J Brinkman, Milan C Richir, Paraskevi Papaioannidou, Robert Likic, Emílio J Sanz, Thierry Christiaens, João N Costa, Fabrizio de Ponti, Milo Gatti, Ylva Böttiger, Cornelis Kramers, Rahul Pandit, Michiel A van Agtmael, Jelle Tichelaar, null null
The European List of Essential Medicines for Medical Education: a modified Delphi study. Clinical pharmacology and therapeutics (2023)
Michiel J Bakkum, Mariëlle G Hartjes, Joost D Piët, Erik M Donker, Robert Likić, Emílio J Sanz, Fabrizio de Ponti, Petra Verdonk, Milan C Richir, Michiel A van Agtmael, Jelle Tichelaar
Using artificial intelligence to create diverse and inclusive medical case vignettes for education. British journal of clinical pharmacology (2023)
Michiel J Bakkum, Bryan J Loobeek, Milan C Richir, Paraskevi Papaioannidou, Robert Likić, Emílio J Sanz, Thierry Christiaens, João N Costa, Lorena Dima, Fabrizio de Ponti, Cornelis Kramers, Jeroen van Smeden, Michiel A van Agtmael, Jelle Tichelaar, null null
Teaching resources for the European Open Platform for Prescribing Education (EurOP 2 E)-a nominal group technique study. NPJ science of learning 7 (1) (2022)
Carlotta Lunghi, Caterina Trevisan, Michele Fusaroli, Valentina Giunchi, Emanuel Raschi, Elisa Sangiorgi, Marco Domenicali, Stefano Volpato, Fabrizio de Ponti, Elisabetta Poluzzi
Strategies and Tools for Supporting the Appropriateness of Drug Use in Older People. Pharmaceuticals (Basel, Switzerland) 15 (8) (2022)
Michiel J Bakkum, Petra Verdonk, Elias G Thomas, Floor van Rosse, Michael Okorie, Paraskevi Papaioannidou, Robert Likić, Emílio J Sanz, Thierry Christiaens, João N Costa, Lorena Dima, Fabrizio de Ponti, Jeroen van Smeden, Michiel A van Agtmael, Milan C Richir, Jelle Tichelaar, null null
A Clinical Pharmacology and Therapeutics Teacher's Guide to Race-Based Medicine, Inclusivity, and Diversity. Clinical pharmacology and therapeutics (2022)
Emanuel Raschi, Michele Fusaroli, Milo Gatti, Paolo Caraceni, Elisabetta Poluzzi, Fabrizio de Ponti
Liver Injury with Nintedanib: A Pharmacovigilance-Pharmacokinetic Appraisal. Pharmaceuticals (Basel, Switzerland) 15 (5) (2022)
Emanuel Raschi, Igor Diemberger, Mario Sabatino, Elisabetta Poluzzi, Fabrizio de Ponti, Luciano Potena
Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction. Expert opinion on pharmacotherapy 23 (3) (2022)
Milo Gatti, Emanuel Raschi, Fabrizio de Ponti
Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 40 (6) (2021)
Young-Mee Lee, Khoa Cao, Michelle Leech, Fabrizio de Ponti
Developing medical artificial intelligence leaders: International university consortium approach. Medical education 55 (11) (2021)
Milo Gatti, Michele Fusaroli, Emanuel Raschi, Ugo Moretti, Elisabetta Poluzzi, Fabrizio de Ponti
Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system. Expert opinion on drug safety 20 (11) (2021)
Milo Gatti, Michele Fusaroli, Emanuel Raschi, Irene Capelli, Elisabetta Poluzzi, Fabrizio de Ponti
Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems. Journal of nephrology (2021)
Milo Gatti, Fabrizio de Ponti
Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities. Pharmaceutics 13 (3) (2021)
Milo Gatti, Elisabetta Poluzzi, Fabrizio de Ponti, Emanuel Raschi
Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis. Drug safety 43 (12) (2021)
Milo Gatti, Fabrizio de Ponti, Federico Pea
Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies. CNS drugs 35 (4) (2021)
Emanuel Raschi, Michele Fusaroli, Andrea Ardizzoni, Elisabetta Poluzzi, Fabrizio de Ponti
Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System. Cancers 13 (8) (2021)
Milo Gatti, Emanuel Raschi, Fabrizio de Ponti
Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis. European journal of clinical pharmacology 77 (2) (2020)
Emanuel Raschi, Gian Poalo Fadini, Igor Diemberger, Elisabetta Poluzzi, Fabrizio de Ponti
SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR? Expert opinion on pharmacotherapy 22 (5) (2020)
Emanuel Raschi, Paolo Caraceni, Elisabetta Poluzzi, Fabrizio de Ponti
Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19? Expert opinion on drug safety 19 (10) (2020)
Emanuel Raschi, Fabrizio de Ponti
Liver injury with direct-acting anticoagulants: has the fog cleared? Heart (British Cardiac Society) 103 (24) (2018)
Emanuel Raschi, Elisabetta Poluzzi, Gian Poalo Fadini, Giulio Marchesini, Fabrizio de Ponti
Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough? Diabetes, obesity & metabolism 20 (12) (2018)
Emanuel Raschi, Igor Diemberger, Benilde Cosmi, Fabrizio de Ponti
ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations-authors' reply. Internal and emergency medicine 13 (4) (2018)
Emanuel Raschi, Matteo Bianchin, Cecilia Fantoni, Walter Ageno, Fabrizio de Ponti, Roberto De Ponti
Evolving cardiovascular uses of direct-acting oral anticoagulants: a paradigm shift on the horizon? Internal and emergency medicine 12 (7) (2017)
Emanuel Raschi, Igor Diemberger, Benilde Cosmi, Fabrizio de Ponti
ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations. Internal and emergency medicine 13 (1) (2017)
A Girardi, S Galletti, E Raschi, A Koci, E Poluzzi, G Faldella, Fabrizio de Ponti
Pattern of drug use among preterm neonates: results from an Italian neonatal intensive care unit. Italian journal of pediatrics 43 (1) (2017)

Fabrizio de Ponti.css-eqlu8i{font-size:small;padding-left:4px;} (F De Ponti, Fabrizio De Ponti)

Publication Activity (10 Years)

Top Topics

Top Venues

Fabrizio de Ponti (F De Ponti, Fabrizio De Ponti)